Selecting lactic acid bacteria for their safety and functionality by use of a mouse colitis model

Applied and Environmental Microbiology

Volumn 72, Issue 9, 2006, Pages 5799-5805

  Daniel, Catherine ^a   Poiret, Sabine ^a   Goudercourt, Denise ^a   Dennin, Veronique ^a   Leyer, Gregory ^b   Pot, Bruno ^a  

^a INSTITUT PASTEUR DE LILLE   (France)

^b Danisco USA Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL ORGANS; CARBOXYLIC ACIDS; DISEASES; HEALTH RISKS; PATIENT TREATMENT;

BACTERIAL TRANSLOCATION; INFLAMMATORY CONDITIONS; INTESTINAL INFLAMMATION;

BACTERIA;

PROBIOTIC AGENT; TRINITROBENZENESULFONIC ACID;

BACTERIAL DISEASE; BACTERIUM; COMPARATIVE STUDY; HEALTH RISK; MODEL; PROBIOTICS; SAFETY; TRANSLOCATION;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL STRAIN; BACTERIAL SURVIVAL; BACTERIAL TRANSLOCATION; CELL STRAIN CACO 2; COLITIS; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE MODEL; DRUG EFFECT; DRUG SAFETY; EVALUATION; HUMAN; HUMAN CELL; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS PARACASEI; LACTOBACILLUS PLANTARUM; LACTOBACILLUS SALIVARIUS; MOUSE; NONHUMAN;

ACUTE DISEASE; ANIMALS; BACTERIAL ADHESION; CACO-2 CELLS; COLITIS; DISEASE MODELS, ANIMAL; FEMALE; GASTROINTESTINAL TRACT; HUMANS; LACTOBACILLUS; MICE; MICE, INBRED BALB C; PROBIOTICS; SAFETY; TRINITROBENZENESULFONIC ACID;

BACTERIA (MICROORGANISMS); LACTOBACILLUS ACIDOPHILUS NCFM; LACTOBACILLUS PARACASEI; LACTOBACILLUS PLANTARUM; LACTOBACILLUS SALIVARIUS;

EID: 33748771708     PISSN: 00992240     EISSN: None     Source Type: Journal    
DOI: 10.1128/AEM.00109-06     Document Type: Article

References (45)

1. Altermann, E., W. M. Russell, M. A. Azcarate-Peril, R. Barrangou, B. L. Buck, O. McAuliffe, N. Souther, A. Dobson, T. Duong, M. Callanan, S. Lick, A. Hamrick, R. Cano, and T. R. Klaenhammer. 2005. Complete genome sequence of the probiotic lactic acid bacterium Lactobacillus acidophilus NCFM. Proc. Natl. Acad. Sci. USA 102:3906-3912.
2. Arpi, M., M. Vancanneyt, J. Swings, and J. J. Leisner. 2003. Six cases of Lactobacillus bacteraemia: identification of organisms and antibiotic susceptibility and therapy. Scand. J. Infect. Dis. 35:404-408.
3. Berg, R. D. 1999. Bacterial translocation from the gastrointestinal tract. Adv. Exp. Med. Biol. 473:11-30.
4. Bradley, P. P., D. A. Priebat, R. D. Christensen, and G. Rothstein. 1982. Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J. Investig. Dermatol. 78:206-209.
5. Charteris, W. P., P. M. Kelly, L. Morelli, and J. K. Collins. 1998. Development and application of an in vitro methodology to determine the transit tolerance of potentially probiotic Lactobacillus and Bifidobacterium species in the upper human gastrointestinal tract. J. Appl. Microbiol. 84:759-768.
6. Chateau, N., A. M. Deschamps, and A. H. Sassi. 1994. Heterogeneity of bile salts resistance in the Lactobacillus isolates of a probiotic consortium. Lett. Appl. Microbiol. 18:42-44.
7. FAO/WHO. 2001. Report of a Joint FAO/WHO expert consultation on evaluation of health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria. World Health Organization and Food and Agriculture Organization of the United Nations, London, Ontario, Canada.
8. Fedorak, R. N., and K. L. Madsen. 2004. Probiotics and the management of inflammatory bowel disease. Inflamm. Bowel Dis. 10:286-299.
9. Foligné, B., C. Grangette, and B. Pot. 2005. Probiotics in IBD: mucosal and systemic routes of administration may promote similar effects. Gut 54:727-728.
10. Foligné, B., S. Nutten, L. Steidler, V. Dennin, D. Goudercourt, A. Mercenier, and B. Pot. 2006. Recommendations for improved use of the murine TNBS-induced colitis model in evaluating anti-inflammatory properties of lactic acid bacteria: technical and microbiological aspects. Dig Dis. Sci. 51:390-400.
11. Fonden, R., R. Bjorneholm, and K. Ohlson. 2000. Lactobacillus F19-a new probiotic strain. Poster presented at the 4th Workshop of the PROBEMO-FAIR CT 96-1028 Project Functional Foods for EU Health in 2000.
12. Gevers, D., G. Huys, and J. Swings. 2001. Applicability of rep-PCR finger-printing for identification of Lactobacillus species. FEMS Microbiol. Lett. 205:31-36.
13. Gill, H. S., and F. Guarner. 2004. Probiotics and human health: a clinical perspective. Postgrad. Med. J. 80:516-526.
14. Hart, A. L., A. J. Stagg, and M. A. Kamm. 2003. Use of probiotics in the treatment of inflammatory bowel disease. J. Clin. Gastroenterol. 36:111-119.
15. Harty, D. W. S., M. Patrikakis, and K. W. Knox. 1993. Identification of Lactobacillus strains isolated from patients with infective endocarditis and comparison of their surface-associated properties with those of other strains of the same species. Microb. Ecol. Health Dis. 6:191-201.
16. Jacobsen, C. N., V. R. Nielsen, A. E. Hayford, P. L. Moller, K. F. Michaelsen, A. Paerregaard, B. Sandstrom, M. Tvede, and M. Jakobsen. 1999. Screening of probiotic activities of forty-seven strains of Lactobacillus spp. by in vitro techniques and evaluation of the colonization ability of five selected strains in humans. Appl. Environ. Microbiol. 65:4949-4956.
17. Josson, K., T. Scheirlinck, F. Michiels, C. Platteeuw, P. Stanssens, H. Joos, P. Dhaese, M. Zabeau, and J. Mahillon. 1989. Characterization of a gram-positive broad-host-range plasmid isolated from Lactobacillus hilgardii. Plasmid 21:9-20.
18. Kruis, W., P. Fric, J. Pokrotnieks, M. Lukas, B. Fixa, M. Kascak, M. A. Kamm, J. Weismueller, C. Beglinger, M. Stolte, C. Wolff, and J. Schulze. 2004. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 53:1617-1623.
19. Kuisma, J., S. Mentula, H. Jarvinen, A. Kahri, M. Saxelin, and M. Farkkila. 2003. Effect of Lactobacillus rhamnosus GG on ileal pouch inflammation and microbial flora. Aliment. Pharmacol. Ther. 17:509-515.
20. Lamine, F., H. Eutamene, J. Fioramonti, L. Bueno, and V. Theodorou. 2004. Colonic responses to Lactobacillus farciminis treatment in trinitrobenzene sulphonic acid-induced colitis in rats. Scand. J. Gastroenterol. 39:1250-1258.
21. Land, M. H., K. Rouster-Stevens, C. R. Woods, M. L. Cannon, J. Cnota, and A. K. Shetty. 2005. Lactobacillus sepsis associated with probiotic therapy. Pediatrics 115:178-181.
22. Llopis, M., M. Antolin, F. Guarner, A. Salas, and J. R. Malagelada. 2005. Mucosal colonisation with Lactobacillus casei mitigates barrier injury induced by exposure to trinitronbenzene sulphonic acid. Gut 54:955-959.
23. Madsen, K., A. Cornish, P. Soper, C. McKaigney, H. Jijon, C. Yachimec, J. Doyle, L. Jewell, and C. De Simone. 2001. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 121:580-591.
24. Maragkoudakis, P. A., G. Zoumpopoulou, C. Miaris, G. Kalantzopoulos, B. Pot, and E. Tsakalidou. 2006. Probiotic potential of Lactobacillus strains isolated from dairy products. Int. Dairy J. 16:189-199.
25. McCarthy, J., L. O'Mahony, L. O'Callaghan, B. Sheil, E. E. Vaughan, N. Fitzsimons, J. Fitzgibbon, G. C. O'Sullivan, B. Kiely, J. K. Collins, and F. Shanahan. 2003. Double blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance. Gut 52:975-980.
26. Mercenier, A., P. Hols, Y. Roussel, G. Perez-Martinez, J. Buesa, M. Wilks, G. Pozzi, E. Remaut, L. Morelli, C. Grangette, V. Monedero, E. Palumbo, B. Foligne, L. Steidler, and S. Nutten. 2004. Screening and construction of probiotic strains with enhanced protective properties against intestinal disorders. Microb. Ecol. Health Dis. 16:86-95.
27. Mimura, T., F. Rizzello, U. Helwig, G. Poggioli, S. Schreiber, I. C. Talbot, R. J. Nicholls, P. Gionchetti, M. Campieri, and M. A. Kamm. 2004. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 53:108-114.
28. Morris, G. P., P. L. Beck, M. S. Herridge, W. T. Depew, M. R. Szewczuk, and J. L. Wallace. 1989. Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology 96:795-803.
29. Nazli, A., P. C. Yang, J. Jury, K. Howe, J. L. Watson, J. D. Soderholm, P. M. Sherman, M. H. Perdue, and D. M. McKay. 2004. Epithelia under metabolic stress perceive commensal bacteria as a threat. Am. J. Pathol. 164:947-957.
30. Neurath, M., I. Fuss, and W. Strober. 2000. TNBS-colitis. Int. Rev. Immunol. 19:51-62.
31. Osman, N., D. Adawi, S. Ahrne, B. Jeppsson, and G. Molin. 2004. Modulation of the effect of dextran sulfate sodium-induced acute colitis by the administration of different probiotic strains of Lactobacillus and Bifidobacterium. Dig. Dis. Sci. 49:320-327.
32. Otte, J. M., and D. K. Podolsky. 2004. Functional modulation of enterocytes by gram-positive and gram-negative microorganisms. Am. J. Physiol. Gastrointest. Liver Physiol. 286:G613-G626.
33. Pavan, S., P. Desreumaux, and A. Mercenier. 2003. Use of mouse models to evaluate the persistence, safety, and immune modulation capacities of lactic acid bacteria. Clin. Diagn. Lab. Immunol. 10:695-701.
34. Peran, L., D. Camuesco, M. Comalada, A. Nieto, A. Concha, M. P. Diaz-Ropero, M. Olivares, J. Xaus, A. Zarzuelo, and J. Galvez. 2005. Preventative effects of a probiotic, Lactobacillus salivarius ssp. salivarius, in the TNBS model of rat colitis. World J. Gastroenterol. 11:5185-5192.
35. Salminen, M. K., H. Rautelin, S. Tynkkynen, T. Poussa, M. Saxelin, V. Valtonen, and A. Jarvinen. 2004. Lactobacillus bacteremia, clinical significance, and patient outcome, with special focus on probiotic L. rhamnosus GG. Clin. Infect. Dis. 38:62-69.
36. Salminen, M. K., S. Tynkkynen, H. Rautelin, M. Saxelin, M. Vaara, P. Ruutu, S. Sarna, V. Valtonen, and A. Jarvinen. 2002. Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland. Clin. Infect. Dis. 35:1155-1160.
37. Sanders, M. E., and T. R. Klaenhammer. 2001. The scientific basis of Lactobacillus acidophilus NCFM functionality as a probiotic. J. Dairy Sci. 84:319-331.
38. Shanahan, F. 2004. Host-flora interactions in inflammatory bowel disease. Inflamm. Bowel Dis. 10:S16-S24.
39. Shanahan, F. 2003. Probiotics: a perspective on problems and pitfalls. Scand. J. Gastroenterol. Suppl.: 34-36.
40. Sheil, B., J. McCarthy, L. O'Mahony, M. W. Bennett, P. Ryan, J. J. Fitzgibbon, B. Kiely, J. K. Collins, and F. Shanahan. 2004. Is the mucosal route of administration essential for probiotic function? Subcutaneous administration is associated with attenuation of murine colitis and arthritis. Gut 53:694-700.
41. Snelling, A. M. 2005. Effects of probiotics on the gastrointestinal tract. Curr. Opin. Infect. Dis. 18:420-426.
42. Steinberg, S. M. 2003. Bacterial translocation: what it is and what it is not. Am. J. Surg. 186:301-305.
43. Vesa, T., P. Pochart, and P. Marteau. 2000. Pharmacokinetics of Lactobacillus plantarum NCIMB 8826, Lactobacillus fermentum KLD, and Lactococcus lactis MG 1363 in the human gastrointestinal tract. Aliment. Pharmacol. Ther. 14:823-828.
44. von Wright, A. 2005. Regulating the safety of probiotics-the European approach. Curr. Pharm. Des. 11:17-23.
45. Walker, D. C., K. Aoyama, and T. R. Klaenhammer. 1996. Electrotransformation of Lactobacillus acidophilus group Al. FEMS Microbiol. Lett. 138:233-237.